Should I buy or sell bluebird bio stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks .

What is bluebird bio's stock price target for 2024?

12 analysts have issued 12-month price objectives for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's stock price to reach $5.87 in the next twelve months. This suggests a possible upside of 509.4% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts .

How have BLUE shares performed in 2024?

bluebird bio's stock was trading at $1.38 at the beginning of 2024. Since then, BLUE shares have decreased by 30.2% and is now trading at $0.9633. View the best growth stocks for 2024 here .

Are investors shorting bluebird bio?

bluebird bio saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 29,750,000 shares, a drop of 12.6% from the March 15th total of 34,040,000 shares. Based on an average daily trading volume, of 9,070,000 shares, the short-interest ratio is currently 3.3 days. View bluebird bio's Short Interest .

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BLUE earnings forecast .

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative trailing twelve-month return on equity of 34.32% and a negative net margin of 419.64%. The company's revenue for the quarter was up 17364.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.92) EPS.

What ETFs hold bluebird bio's stock?

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON) . Horizon Kinetics Medical ETF (MEDX) .

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com . Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK) , BioMarin Pharmaceutical (BMRN) , Puma Biotechnology (PBYI) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Incyte (INCY) , Micron Technology (MU) , Alibaba Group (BABA) and (MDVN) (MDVN) .

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain , Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole , Jessica Whitten , Nick Leschly , Richard A Colvin and Thomas J Klima. View institutional ownership trends .

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLUE

bluebird bio (BLUE) Stock Price, News & Analysis

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Free BLUE Stock Alerts

$0.96

0.00 (-0.34%)

(As of 09:03 AM ET)

Compare

Today's Range: $0.96
▼
$0.96
50-Day Range: $0.94
▼
$1.75
52-Week Range: $0.88
▼
$5.53

Volume: 23,799 shs
Average Volume: 8.87 million shs
Market Capitalization: $104.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.87

Get bluebird bio alerts:

bluebird bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 509.4% Upside
$5.87 Price Target
Short Interest: Healthy
27.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.10
Based on 22 Articles This Week
Insider Trading: Selling Shares
$4,134 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.78) to ($1.72) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

413th out of 913 stocks

Biological Products, Except Diagnostic Industry

62nd out of 149 stocks

3.2

Analyst's Opinion

Consensus Rating
bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
bluebird bio has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
27.21% of the outstanding shares of bluebird bio have been sold short.
Short Interest Ratio / Days to Cover
bluebird bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in bluebird bio has recently decreased by 12.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
bluebird bio does not currently pay a dividend.
Dividend Growth
bluebird bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLUE.

1.7

News and Social Media Coverage

News Sentiment
bluebird bio has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for bluebird bio this week, compared to 5 articles on an average week.
Search Interest
Only 42 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -51% compared to the previous 30 days.
MarketBeat Follows
Only 21 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,134.00 in company stock.
Percentage Held by Insiders
Only 2.10% of the stock of bluebird bio is held by insiders.
Percentage Held by Institutions
87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for bluebird bio are expected to grow in the coming year, from ($1.78) to ($1.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of bluebird bio is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of bluebird bio is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
bluebird bio has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLUE Stock News Headlines

April 17, 2024 | msn.com

bluebird bio (BLUE) Price Target Decreased by 7.15% to 4.24

April 17, 2024 | prnewswire.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE

April 18, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

April 16, 2024 | prnewswire.com

Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm

April 16, 2024 | msn.com

TD Cowen says sickle cell therapies may get higher CMS payments

April 16, 2024 | americanbankingnews.com

bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of "Hold" from Analysts

April 15, 2024 | prnewswire.com

BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit

April 15, 2024 | fool.com

Is Bluebird Bio Stock a Buy?

April 18, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

April 15, 2024 | prnewswire.com

bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUE

April 14, 2024 | stockhouse.com

ROSEN, LEADING TRIAL ATTORNEYS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE

April 14, 2024 | markets.businessinsider.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue

April 13, 2024 | markets.businessinsider.com

ROSEN, A Leading Law Firm, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE

April 13, 2024 | fool.com

Better Buy: Bluebird Bio Vs. Novavax

April 12, 2024 | prnewswire.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE

April 12, 2024 | businesswire.com

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against BlueBird Bio, Inc. (NASDAQ: BLUE)

April 12, 2024 | businesswire.com

BLUE Shareholders with Significant Losses are Urged to Contact Robbins LLP to Discuss the bluebird bio, Inc. Class Action

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE

April 12, 2024 | prnewswire.com

Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

April 11, 2024 | stockhouse.com

Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BLUE

April 11, 2024 | markets.businessinsider.com

ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE

April 11, 2024 | fool.com

Is This Beaten-Down Stock a Good Acquisition Target?

April 11, 2024 | businesswire.com

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2024 | prnewswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE

April 10, 2024 | prnewswire.com

BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit

April 10, 2024 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

April 10, 2024 | prnewswire.com

May 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUE

See More Headlines

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BLUE
CUSIP: N/A
CIK: 1293971
Web: www.bluebirdbio.com
Phone: (339) 499-9300
Fax: N/A
Employees: 323
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.87
High Stock Price Target: $13.00
Low Stock Price Target: $1.02
Potential Upside/Downside: +509.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-266,580,000.00
Net Margins: -419.64%
Pretax Margin: -419.50%
Return on Equity: -34.32%
Return on Assets: -14.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.55
Quick Ratio: 1.42

Sales & Book Value

Annual Sales: $3.60 million
Price / Sales: 29.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.37 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 109,340,000
Free Float: 107,040,000
Market Cap: $105.33 million
Optionable: Optionable
Beta: 0.74

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Andrew Obenshain (Age 50)
President, CEO & Director
Comp: $1.04M
Mr. Thomas J. Klima (Age 52)
Chief Commercial Officer & COO
Comp: $654.97k
Mr. Richard A. Colvin M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $696.24k
Mr. Christopher Krawtschuk CPA (Age 50)
CFO, Principal Accounting Officer & Treasurer
Mr. Joseph D. Vittiglio Esq. (Age 52)
J.D., Chief Legal & Business Officer and Secretary
Jess Rowlands
Head of Corporate Communications
Ms. Andrea Walton
Chief People Officer
Mr. Kasra Kasraian
Senior Vice President of Technical Development & Operations
Mr. Scott Shoemaker
Senior Vice President of Quality
Ms. Sarah Alspach
Senior Vice President of External Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.
What is bluebird bio's stock price target for 2024?: 12 analysts have issued 12-month price objectives for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's stock price to reach $5.87 in the next twelve months. This suggests a possible upside of 509.4% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.
How have BLUE shares performed in 2024?: bluebird bio's stock was trading at $1.38 at the beginning of 2024. Since then, BLUE shares have decreased by 30.2% and is now trading at $0.9633.
View the best growth stocks for 2024 here.
Are investors shorting bluebird bio?: bluebird bio saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 29,750,000 shares, a drop of 12.6% from the March 15th total of 34,040,000 shares. Based on an average daily trading volume, of 9,070,000 shares, the short-interest ratio is currently 3.3 days.
View bluebird bio's Short Interest.
When is bluebird bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BLUE earnings forecast.
How were bluebird bio's earnings last quarter?: bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative trailing twelve-month return on equity of 34.32% and a negative net margin of 419.64%. The company's revenue for the quarter was up 17364.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.92) EPS.

What ETFs hold bluebird bio's stock?: ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON).Horizon Kinetics Medical ETF (MEDX).
What is Nick Leschly's approval rating as bluebird bio's CEO?: 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.
What other stocks do shareholders of bluebird bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).
Who are bluebird bio's major shareholders?: bluebird bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends.
How do I buy shares of bluebird bio?: Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

bluebird bio (BLUE) Stock Price, News & Analysis

bluebird bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About bluebird bio Stock (NASDAQ:BLUE)

BLUE Stock Price History

BLUE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BLUE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™